Results 91 to 100 of about 7,935 (218)

The Proctitis Paradox: Refractory Ulcerative Proctitis Associated With Development of Disease Complications in a Multicenter South Australian Cohort

JGH Open, Volume 10, Issue 9, September 2026.
ABSTRACT Background Despite limited extent, patients with ulcerative proctitis (UP) can suffer from debilitating symptoms, complications, and risk of disease extension. The aim was to provide a contemporary real‐world insight into the management and outcomes of UP.
Sreecanth S. Raja, Samuel P. Costello, Alexandra Sadler, Nicholas Wan, Bhuwan Tandon, Dharshan Sathananthan, Kate D. Lynch, Chris K. Rayner, Suzanne Edwards, Robert V. Bryant   +9 more
wiley   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 6, Page 729-747, September 2026.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins, Srinivas Kamath, Rachel H. Davis, Samuel P. Costello, Robert V. Bryant, Alice S. Day, Paul Joyce   +6 more
wiley   +1 more source

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

Journal of Gastroenterology and Hepatology, Volume 41, Issue 9, Page 2709-2720, September 2026.
ABSTRACT Background and Aim Upadacitinib, a selective Janus kinase 1 inhibitor, is approved to treat moderately to severely active ulcerative colitis (UC). This post hoc subanalysis evaluated the efficacy, safety, and pharmacokinetics of upadacitinib in patients in East Asia. Methods U‐ACHIEVE (UC1; NCT02819635) and U‐ACCOMPLISH (UC2; NCT03653026) were
Shu Chen Wei, Hiroshi Nakase, Byong Duk Ye, Kang Chao, Hsin‐Yun Wu, Jason Eccleston, Xuan Yao, Hannah Palac, Mohamed‐Eslam F. Mohamed, Ana Victoria Ponce‐Bobadilla, Smitha Suravaram, Elena Marced Barrachina, Tadakazu Hisamatsu, Xiang Gao   +13 more
wiley   +1 more source

Immunosuppressants in modern approaches to treatment of inflammatory bowel diseases

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2013
Aim of investigation. To characterize frequency of TPMT gene mutations in patients with inflammatory bowel diseases (IBD) with myelosuppression and to estimate value of these mutations in prognosis of myelosuppression development in patients receiving ...
O. B. Schukina, A. G. Kharitonov, A. M. Kharitidis, T. E. Ivashchenko, Yu. A. Nasykhova, T. V. Gabrusskaya, A. Yu. Baranovsky   +6 more
doaj  

Optimising use of thiopurines in inflammatory bowel disease

, 2017
Introduction: Thiopurines are central to inflammatory bowel disease (IBD) therapeutics, either as monotherapy or in combination with newer biologic therapies, however it is only recently that focus has increased on improving effectiveness and ...
Robin J. Dart, Irving, Peter M.; id_orcid, Peter M. Irving, Dart, Robin J.   +3 more
core   +1 more source

Hypoxanthine in the microenvironment can enable thiopurine resistance in acute lymphoblastic leukemia

Frontiers in Oncology
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with relapse being a major obstacle to successful treatment. Our understanding of the mechanisms driving chemotherapy resistance and ultimately relapse in leukemia remains ...
Xiaohong Wang, Xiaohong Wang, Jason Ostergaard, Jason Ostergaard, Jongseok Kang, Jongseok Kang, Grace Sagong, Grace Sagong, Rachel Twite, Rachel Twite, Andrea Vargas-Morales, Andrea Vargas-Morales, Peter M. Gordon, Peter M. Gordon   +13 more
doaj   +1 more source

Thiopurines Induce Oxidative Stress in T-Lymphocytes: A Proteomic Approach

Mediators of Inflammation, 2015
Thiopurines are extensively used immunosuppressants for the treatment of inflammatory bowel disease (IBD). The polymorphism of thiopurine S-methyltransferase (TPMT) influences thiopurine metabolism and therapy outcome. We used a TPMT knockdown (kd) model
Misbah Misdaq, Sonia Ziegler, Nicolas von Ahsen, Michael Oellerich, Abdul R. Asif   +4 more
doaj   +1 more source

The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study

Therapeutic Advances in Gastroenterology
Background: Thiopurines are commonly used to treat inflammatory bowel disease but withdrawal due to side effects are common. Thioguanine has been suggested to be better tolerated than conventional thiopurines.
Helena Gensmyr-Singer, Mårten Werner, Pontus Karling   +2 more
doaj   +1 more source

Histological remission of autoimmune hepatitis after the addition of allopurinol and azathioprine dose reduction

Autopsy and Case Reports, 2017
The standard therapy for some autoimmune diseases consists of a combination of corticosteroids and thiopurines. In non-responders to thiopurine drugs, the measurement of the metabolites of azathioprine, 6-thioguanine, and 6-methylmercaptopurine, can be a
Ana Luiza Vilar Guedes, Adriana Ribas Andrade, Vinicius Santos Nunes, Fabiana Roberto Lima, Evandro Sobroza de Mello, Suzane Kioko Ono, Débora Raquel Benedita Terrabuio, Eduardo Luiz Rachid Cançado   +7 more
doaj   +1 more source

Microbial metabolism of thiopurines: a method to measure thioguanine nucleotides

, 2016
Thiopurines are anti-inflammatory prodrugs. We hypothesised that bacteria may contribute to conversion to active drug. Escherichia coli strain DH5α was evaluated to determine whether it could metabolise the thiopurine drugs, thioguanine or mercaptopurine,
Cuiv, Paraic O, Florin, Timothy H.J., Duley, John A., Oancea, Iulia, Florin, Timothy Fij, Duley, John A, Ó Cuív, Páraic, Florin, Timothy H. J., Movva, Ramya, Lobb, Michael   +9 more
core   +1 more source